Your session is about to expire
← Back to Search
Topical Agent
TAT4 Gel concentration A for Nasolabial Folds
Phase 1
Waitlist Available
Research Sponsored by Topokine Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 days
Summary
This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of skin for 14 days.
Eligible Conditions
- Lipoatrophy
- Nasolabial Folds
- Lipodystrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 21 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Event rates
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: TAT4 Gel concentration BExperimental Treatment1 Intervention
TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
Group II: TAT4 Gel concentration AExperimental Treatment1 Intervention
TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
Group III: PlaceboPlacebo Group1 Intervention
Placebo product once daily to 50 cm2 for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TAT4 Gel concentration A
2014
Completed Phase 1
~20
TAT4 Gel concentration B
2014
Completed Phase 1
~20
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Topokine Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
660 Total Patients Enrolled
1 Trials studying Nasolabial Folds
111 Patients Enrolled for Nasolabial Folds
Share this study with friends
Copy Link
Messenger